Asa Morton, MD
Ophthalmic Plastic and Reconstructive Surgery · San Diego, CANPI 1780669283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,958 of the $12,063 with a category attached, or 66.0%. 12 manufacturers reported payments, led by Amgen at 48.5% of the total. Reporting peaked in 2021 at $5,458 and has fallen 82.6% since, to $952 in 2025.
Across 143 payments — averaging $84.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- AbbVie$5K
- Biotissue Holdings Inc.$986
- Argenx US, Inc.$198
- Sight Sciences, Inc.$162
- Alcon$116
- plus $153 from 6 others
What the payments were for
- Speaking & faculty fees$7,95866%
- Travel & lodging$8607%
- Food & beverage$3,19927%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 79 | $5,853 |
| AbbVie(2 entities) | 43 | $4,595 |
| Biotissue Holdings Inc. | 7 | $986 |
| Argenx US, Inc. | 2 | $198 |
| Sight Sciences, Inc. | 3 | $162 |
| Alcon | 2 | $116 |
| Tarsus Pharmaceuticals, Inc. | 1 | $40 |
| Bausch & Lomb Americas Inc. | 2 | $33 |
| Si-bone, Inc. | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$4,620
- Prokera$860
- AmnioGraft$860
- AmnioGuard$860
- OMNI(R) SURGICAL SYSTEM (US)$125
How this compares
$12,063 in reported general payments places this provider in the 75th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 227 | $2,048 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 42 | $1,528 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $203 |
| Prednisone | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in San Diego
- Cindy OcranSan Diego$2K
- Allison McCoySan Diego$526
- Marjan FaridIrvine$742K
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.